1. Home
  2. YOOV vs SGMT Comparison

YOOV vs SGMT Comparison

Compare YOOV & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Concorde International Group Ltd Class A Ordinary Shares

YOOV

Concorde International Group Ltd Class A Ordinary Shares

N/A

Current Price

$0.62

Market Cap

158.7M

ML Signal

N/A

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$7.24

Market Cap

169.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
YOOV
SGMT
Founded
N/A
2006
Country
Singapore
United States
Employees
109
N/A
Industry
Diversified Commercial Services
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
158.7M
169.4M
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
YOOV
SGMT
Price
$0.62
$7.24
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$26.13
AVG Volume (30 Days)
4.9M
1.3M
Earning Date
N/A
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.36
$4.50
52 Week High
$1.11
$11.41

Technical Indicators

Market Signals
Indicator
YOOV
SGMT
Relative Strength Index (RSI) 60.37 52.32
Support Level $0.36 $7.09
Resistance Level $0.84 $7.39
Average True Range (ATR) 0.15 0.43
MACD 0.02 0.06
Stochastic Oscillator 35.33 58.17

Price Performance

Historical Comparison
YOOV
SGMT

About YOOV Concorde International Group Ltd Class A Ordinary Shares

Concorde International Group Ltd is an integrated security services provider that combines physical manpower and technology to deliver effective security solutions. The company offers a range of services to enhance security and safety: (1) i-Guarding Services; (2) Man-Guarding Services; and (3) Consultancy and Training Services. Its i-Guarding Services leverages technology to increase efficiency, with a mobile platform and cluster aggregation model of a higher skillset workforce. It has two operating segments, which are (i) security services; and (ii) training school. The Majority revenue is generated from Security Services.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: